Hold Your Horses, VIVUS Investors

Shares of VIVUS (NASDAQ: VVUS  ) were up 10.5% today, after news that sales were up for November for the company's obesity drug, Qsymia. This may suggest that some of the company's new marketing strategies for the drug may be turning sluggish sales around. But is the drug finally gaining momentum, or is it just a volatile cyclical stock at the moment? Motley Fool health care analyst Max Macaluso gives us his thoughts on how and when we'll know where VIVUS is headed.

The potential market for obesity drugs is massive, but so are the risks. If you're looking for more information on the top two obesity-drug players, grab copies of our premium research reports on Arena Pharmaceuticals and VIVUS today. In the reports, our senior biotech analyst, Brian Orelli, Ph.D., breaks down each company's strengths and weaknesses, and explains the critical issues you need to know about. News in this space moves fast, so both reports come with a full year of updates. Click now for exclusive information on Arena and VIVUS.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2158595, ~/Articles/ArticleHandler.aspx, 9/2/2014 7:45:30 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement